VANIQA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VANIQA (VANIQA).
Irreversible inhibitor of ornithine decarboxylase, reducing polyamine synthesis and decreasing hair growth.
| Metabolism | Not extensively metabolized; minor hepatic metabolism via unknown pathways. |
| Excretion | Renal: ~44% as unchanged drug; biliary/fecal: minimal (not systematically studied in humans; based on animal data, ~33% fecal). |
| Half-life | Terminal elimination half-life: Approximately 8 hours (range 6-10 hours) following topical application; clinical context: supports twice-daily application. |
| Protein binding | Not determined; eflornithine does not bind significantly to plasma proteins (estimated <10% based on physicochemical properties). |
| Volume of Distribution | Not systematically reported for topical VANIQA; systemic absorption after topical application is low (<1% of applied dose); Vd not calculated. |
| Bioavailability | Topical: Systemic bioavailability <1% (based on urinary excretion of unchanged drug). Oral: Not applicable (VANIQA is topical only). |
| Onset of Action | Topical: Clinical effect (reduction of facial hair growth) typically observed after 4-8 weeks of twice-daily use. |
| Duration of Action | Topical: Growth reduction persists with continued use; hair regrowth returns to baseline within 8 weeks after discontinuation. |
| Molecular Weight | 236.3 |
Apply a thin layer of 13.9% cream to affected areas of face and adjacent chin twice daily, at least 8 hours apart.
| Dosage form | CREAM |
| Renal impairment | No dosage adjustment required for renal impairment. |
| Liver impairment | No dosage adjustment required for hepatic impairment. |
| Pediatric use | Safety and efficacy in pediatric patients below 12 years have not been established. |
| Geriatric use | No specific dosage adjustment recommended; use caution due to potential age-related renal and hepatic function decline. |
| 1st trimester | No adequate studies in pregnant women; animal studies have shown embryotoxicity at high doses. Use only if potential benefit justifies risk. |
| 2nd trimester | No adequate studies in pregnant women; animal studies have shown fetotoxicity at high doses. Use only if potential benefit justifies risk. |
| 3rd trimester | No adequate studies in pregnant women; animal studies have shown fetotoxicity at high doses. Use only if potential benefit justifies risk. |
Clinical note
Comprehensive clinical and safety monograph for VANIQA (VANIQA).
| Placental transfer | It is unknown whether eflornithine crosses the placenta. However, based on molecular weight (236.3 Da) and animal studies, placental transfer is possible. |
| Breastfeeding | It is not known whether eflornithine is excreted in human milk. Due to potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to eflornithine or any component of the formulation
| Precautions | May cause local skin irritation (e.g., redness, burning, stinging), Avoid contact with eyes, mouth, and mucous membranes, Not studied in men or children |
| Food/Dietary | No significant food interactions. Avoid alcohol if skin irritation occurs as it may exacerbate dryness or redness. |
| Clinical Pearls | Vaniqa (eflornithine) is a topical cream for reducing unwanted facial hair in women. It inhibits ornithine decarboxylase, slowing hair growth. Clinical effect is seen after 4-8 weeks of twice-daily use. Do not use on irritated or broken skin. Combine with other hair removal methods; Vaniqa does not remove existing hair. |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | Pregnancy Category C. Animal studies have shown teratogenic effects at doses equivalent to human exposure, but no adequate human studies. Risk cannot be ruled out; use only if clearly needed and benefit outweighs potential fetal risk. |
| Fetal Monitoring | Monitor for maternal adverse effects (e.g., skin irritation, hearing loss) and fetal growth via ultrasound if used during pregnancy. |
| Fertility Effects | No significant fertility impairment observed in animal studies; no human data. |
| Patient Advice | Apply a thin layer twice daily to affected areas of face and chin, at least 5 minutes after cleansing. · Continue using other hair removal methods (e.g., shaving, plucking) as needed; Vaniqa slows regrowth. · Avoid contact with eyes, nostrils, and lips. Wash hands after application. · Results may be seen within 4-8 weeks; if no improvement after 6 months, discontinue use. · Report any severe skin irritation, rash, or signs of infection to your healthcare provider. · Do not use on sunburned, broken, or irritated skin. · Use sun protection (sunscreen, hat) as skin may be more sensitive to sun. · Not for use by pregnant or breastfeeding women without consulting a doctor. |